SEARCH

SEARCH BY CITATION

References

  • 1
    Enstrom JE, Austin DF. Interpreting cancer survival rates. Science 1977; 195: 84751.
  • 2
    Measurement of progress against cancer. Extramural Committee to Assess Measures of Progress Against Cancer. J Natl Cancer Inst 1990; 82: 82535.
  • 3
    Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283: 29758.
  • 4
    Bailar JC 3rd, Gornik HL. Cancer undefeated. N Engl J Med 1997; 336: 156974.
  • 5
    Berrino F, Micheli A, Sant M, Capocaccia R. Interpreting survival differences and trends. Tumori 1997; 83: 916.
  • 6
    Elandt-Johnson RC. Definition of rates: some remarks on their use and misuse. Am J Epidemiol 1975; 102: 26771.
  • 7
    Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187220.
  • 8
    Begg CB, Schrag D. Attribution of deaths following cancer treatment. J Natl Cancer Inst 2002; 94: 10445.
  • 9
    Engel LW, Strauchen JA, Chiazze L Jr, Heid M. Accuracy of death certification in an autopsied population with specific attention to malignant neoplasms and vascular diseases. Am J Epidemiol 1980; 111: 99112.
  • 10
    Percy C, Stanek E 3rd, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981; 71: 24250.
  • 11
    Welch HG, Black WC. Are deaths within 1 month of cancer-directed surgery attributed to cancer? J Natl Cancer Inst 2002; 94: 106670.
  • 12
    Talback M, Rosen M, Stenbeck M, Dickman PW. Cancer patient survival in Sweden at the beginning of the third millennium – predictions using period analysis. Cancer Causes Control 2004; 15: 96776.
  • 13
    Brenner H, Gefeller O, Hakulinen T. Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004; 40: 32635.
  • 14
    Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 16048.
  • 15
    Surveillance E, and End Results (SEER) Program. SEER*Stat Database: Incidence – SEER 9 Regs Public-Use, 2004 Sub (1973–2002). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2005.
  • 16
    Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982; 38: 93342.
  • 17
    Surveillance Research Program NCI. SEER*Stat Software. Bethesda, MD: National Cancer Institute, 2006.
  • 18
    Ganti AK, Mulshine JL. Lung cancer screening: panacea or pipe dream? Ann Oncol 2005; 16(Suppl. 2): ii2159.
  • 19
    Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 197784.
  • 20
    Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 1996; 88: 121621.
  • 21
    Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 98190.
  • 22
    Varenhorst E, Garmo H, Holmberg L et al. The National Prostate Cancer Register in Sweden 1998–2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005; 39: 11723.
  • 23
    Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90: 16273.
  • 24
    Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 178492.
  • 25
    Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005; 293: 124556.
  • 26
    Day NE. Overdiagnosis and breast cancer screening. Breast Cancer Res 2005; 7: 2289.
  • 27
    Hoff G, Bretthauer M. The science and politics of colorectal cancer screening. PLoS Med 2006; 3: 0e36; quiz e104.
  • 28
    Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 564450.
  • 29
    Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 47692.
  • 30
    MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 45760.
  • 31
    Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 63846.
  • 32
    Birgisson H, Talback M, Gunnarsson U, Pahlman L, Glimelius B. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol 2005; 31: 84553.
  • 33
    Adami HO. What is progress against cancer? Cancer Causes Control 1993; 4: 4837.